絞り込み

16731

広告

Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?

著者 Scoccianti G , Totti F , Scorianz M , Baldi G , Roselli G , Beltrami G , Franchi A , Capanna R , Campanacci DA
Clin Orthop Relat Res.2018 Sep ; 476(9):1783-1790.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (57view , 0users)

Full Text Sources

Medical

Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used for treatment of giant cell tumor of bone (GCTB). In GCTB, denosumab has been used as a single agent in patients with inoperable tumors; it also has been used before surgery in some patients with the aim to downstage the tumor to facilitate a joint-preserving procedure (curettage) rather than a resection. However, few studies are available evaluating the benefits and risks of denosumab for the latter indication.
PMID: 30778015 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード